세계 자궁내 피임기구(IUD) 시장 규모는 2023년 48억 5,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 5.81%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 67억 7,000만 달러에 달할 것으로 예상됩니다. 자궁내 피임기구(IUD) 시장은 가족계획에 대한 인식 증가, 계획된 임신과 늦은 임신 증가로 인한 의도하지 않은 임신의 높은 비율, 피임에 대한 정부의 다양한 건강 관리 이니셔티브 등의 요인으로 인해 2024년부터 2030년까지 예측 기간 동안 긍정적인 시장 성장을 보일 전망입니다.
자궁내 피임기구(IUD) 시장의 주요 촉진요인 중 하나는 가족계획에 대한 인식이 높아진 것. 2020년 11월, 세계보건기구(WHO)는 피임법에 대한 전 세계 데이터를 발표했는데, 2019년에 11억 명의 가임기(15-49세) 여성들이 가족계획이 필요하며, 그 중 8억 4,200만 명이 피임법을 사용하고 있으며, 2억 7,000만 명이 피임에 대한 미충족 수요를 가지고 있다고 밝혔습니다.
가족계획은 임신을 늦추거나 자녀 수를 제한하기 위해 피임의 필요성을 추구하는 최근 부모들의 대부분 선택입니다. 따라서 피임 수요 증가는 IUD에 대한 수요를 증가시켜 예측 기간 동안 자궁내 피임기구(IUD) 시장의 성장을 가속할 것입니다.
또한, 자궁내 피임기구(IUD) 시장의 상승을 가져오는 또 다른 중요한 요인은 의도하지 않은 임신의 비율이 높다는 것입니다. 전 세계 중저소득 국가에서 매년 7,400만 명의 여성이 의도치 않은 임신을 하고 있으며, 매년 2,500만 건의 인공임신중절과 47,000건의 산모 사망을 유발하고 있습니다.
이 보고서는 세계 자궁내 피임기구(IUD) 시장을 조사했으며, 시장 개요와 함께 제품 유형별, 최종 사용자 유형별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Intrauterine Devices Market By Type (Hormonal Intrauterine And Copper Intrauterine), By End-User Type (Hospitals, Gynaecology Clinics And Community Health Care Centres), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increase in awaremness in family planning and high rates of unintended pregnancies.
Global Intrauterine Devices Market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030. The Intrauterine Devices market is witnessing a positive market growth owing to the factors such as, increasing awareness about family planning, high rates of unintended pregnancies which pay way for increased tendency for planned or delayed pregnancies, various healthcare initiatives by government around contraception, are all contributing to the growth of the Intrauterine Devices Market during the forecast period from 2024-2030.
Intrauterine Devices Market Dynamics:
One of the main drivers of the Intrauterine Devices (IUDs) market is the increasing awareness about family planning. In November 2020, World Health Organization (WHO) released worldwide data on contraceptive methods that in 2019, 1.1 billion women of reproductive age (15-49) need family planning, of whom 842 million use contraceptive methods, and 270 million have unmet need for contraception.
Family planning is a choice of most of the parents these days which demand the need of contraceptives to delay pregnancies or limit the number of children, since IUDs are better than other contraceptives methods as they are 99% effective and provide long term protection against pregnancy. Therefore, increase in contraceptive demand will increase the demand of IUDs, thereby propelling the growth of the intrauterine devices market in the forecast period (2024-2030).
Moreover, another key factor that may be responsible for the rise in intrauterine devices market is high rates of unintended pregnancies. Around the globe in low and middle income countries, 74 million women have unintended pregnancies annually resulting in 25 million abortions and 47000 maternal deaths each year.
Additionally, according to the WHO in November 2022, worldwide approximately 6 in 10 unintended pregnancies results in induced abortion from which 45% of abortions are unsafe, can lead to death of mother. Worldwide each year approximately 73 million induced abortions takes place. Each year 4.7-13.2% maternal deaths takes place due to unsafe abortions, nearly 220 maternal death per 100,000 happens in developing region. Therefore, to overcome maternal deaths, contraceptives such as IUDs should be used which can reduce unintended pregnancies.
Thus, the use of IUDs can help women for family planning concerns to prevent unintended pregnancies, unsafe abortions and maternal deaths. Therefore, because of the above mentioned factors, an increase in IUD market will be seen in forecast period.
However, intrauterine devices can cause serious health issues such as infection, bleeding, pain, among others moreover, it does not protect against Sexually Transmitted Diseases (STDs), thus this become challenging which can slow down the intrauterine devices market growth.
COVID-19 pandemic has impacted the market for intrauterine devices. Lockdown restrictions in many countries confined people to be at their homes. Hence, birth controls, sexual and reproductive needs were out of their reach due to which unwanted pregnancies increased. However, with masses being vaccinated, the intrauterine devices market has picked momentum and is expected to grow during the forecast period.
Intrauterine Devices Market Segment Analysis:
Intrauterine Devices Market By Type (Hormonal Intrauterine and Copper Intrauterine), By End-User Type (Hospitals, Gynecology Clinics and Community Health Care Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the by type segment of IUDs market, the hormonal intrauterine are estimated to hold the highest market share during the forecast period (2024-2030).
According to family planning NSW, both hormonal IUDs and copper IUDs are very effective, more than 99%. However, hormonal IUDs are found to be 99.8% effective and copper IUDs are 99.2% effective which means hormonal IUDs are more effective than copper IUDs.
Therefore, hormonal IUDs are preferred more because it contains hormone which helps to reduce period pain as well as bleeding while copper IUDs can make heavier periods and can cause cramps.
In August 2022, Bayer announced that US Food and Drug Administration (FDA) has approved Supplemental New Drug application (sNDA) to extend the life span of Mirena IUD.
In October 2019, FDA approved Medicines360's LILETTA, alevonorgestrel-releasing intrauterine system 52 mg which can prevent pregnancy for up to six years.
In May 2018, Medicines360 announced the launch of its hormonal IUD Avibela in Madagascar.
Furthermore, factors such as reduce in period pain and bleeding, supports the hormonal IUDs demand thereby will drive the growth of overall intrauterine devices market during the forecast period from 2024-2030.
North America is expected to dominate the overall Intrauterine Devices:
Among all the regions, North America is expected to account for the largest share in the global intrauterine devices, increased tendency for planned or delayed pregnancies, and government initiatives towards family planning awareness, are all contributing to the growth of the intrauterine devices market in the region.
Tendency of planned pregnancies have increased due to increasing female employment, additional education of women and medical reasons can be the factors responsible for planned/delayed pregnancies. Therefore, use of contraceptive methods such as IUDs can be preferred to delay pregnancies, they are safe, effective and long lasting methods, and increase in IUDs demand in turn would provide a conducive growth environment for North American region IUDs market growth.
Moreover, governmental initiatives such as in October 2020, Pan American Health Organization (PAHO) in collaboration with United Nations Population Fund (UNPFA) and WHO, conducted an adolescent pregnancy prevention week from 18th October - 24th October 2020. They hosted webinar, technical meeting on adolescent pregnancy prevention and risks related to it in Caribbean.
Thus, factors such as planned delayed pregnancies and healthcare initiatives by government help people to understand the risks related to unintended pregnancies and advantages of family planning which also results in population growth control. These programmes make people aware about use of contraceptives therefore, increasing the demand of IUDs which in turn would provide a conducive growth environment for North American region intrauterine devices market.
Intrauterine Devices Market Key Players:
Some of the key market players operating in the intrauterine devices market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.
Recent Developmental Activities in the Intrauterine Devices:
Key Takeaways from the Intrauterine Devices Market Report Study
Target Audience who can be benefited from this Intrauterine Devices Market Report Study
Frequently Asked Questions for Intrauterine Devices:
Intrauterine Devices are small devices which are inserted inside the womb (uterus) of women by doctors to prevent pregnancies, which give protection against pregnancy for 5-10 years. These are one form of long-acting reversible birth control.
Global Intrauterine Devices Market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030.
The Intrauterine Devices market is witnessing a positive market growth owing to the factors such as, family planning, increased tendency for planned delayed pregnancies, high rates of unintended pregnancies, , and healthcare initiatives by government.
Some of the key market players operating in the Intrauterine Devices Market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.
North America is expected to hold the highest share in the revenue of intrauterine devices market during the forecast period. High abortion rates, healthcare initiatives by government for family planning and to prevent unintended pregnancies will increase the demand for intrauterine devices in North America leading to a rise in the overall intrauterine devices market growth in this region.